Cargando…

Theranostics in nuclear medicine practice

The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of pote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yordanova, Anna, Eppard, Elisabeth, Kürpig, Stefan, Bundschuh, Ralph A, Schönberger, Stefan, Gonzalez-Carmona, Maria, Feldmann, Georg, Ahmadzadehfar, Hojjat, Essler, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633297/ https://www.ncbi.nlm.nih.gov/pubmed/29042793 http://dx.doi.org/10.2147/OTT.S140671

Ejemplares similares

Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results
por: Khawar, Ambreen, et al.
Publicado: (2019)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Theranostic Advances in Breast Cancer in Nuclear Medicine
por: Vahidfar, Nasim, et al.
Publicado: (2021)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
por: Gaertner, Florian C., et al.
Publicado: (2017)

It is time to move forward into the era of Theranostics
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2018)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis—Challenges and Critical Points in Implementation into Clinical Routine
por: Meisenheimer, Michael, et al.
Publicado: (2020)

Ethanol effects on (68)Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing
por: Meisenheimer, Michael, et al.
Publicado: (2019)

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases
por: Mayer, Karin, et al.
Publicado: (2020)

Radiolabeling Strategies of Nanobodies for Imaging Applications
por: Küppers, Jim, et al.
Publicado: (2021)

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
por: Yordanova, Anna, et al.
Publicado: (2017)

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
por: Thomas, Lena, et al.
Publicado: (2017)

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
por: Khurshid, Zain, et al.
Publicado: (2018)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Nuclear Medicine in Acute Care
por: Assadi, Majid, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy
por: Moazemi, Sobhan, et al.
Publicado: (2020)

Effect of Endobronchial Valve Therapy on Pulmonary Perfusion and Ventilation Distribution
por: Pizarro, Carmen, et al.
Publicado: (2015)

Diagnostic accuracy of [(99m)Tc]Tc-Sestamibi in the assessment of thyroid nodules
por: Yordanova, Anna, et al.
Publicado: (2017)

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020)

Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer
por: Eppard, Elisabeth, et al.
Publicado: (2017)

Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons
por: Bundschuh, Ralph A., et al.
Publicado: (2019)

Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2014)

A Novel Radiomics-Based Tumor Volume Segmentation Algorithm for Lung Tumors in FDG-PET/CT after 3D Motion Correction—A Technical Feasibility and Stability Study
por: Bundschuh, Lena, et al.
Publicado: (2022)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Optimized production, purification, and radiolabeling of the (203)Pb/(212)Pb theranostic pair for nuclear medicine
por: McNeil, Brooke L., et al.
Publicado: (2023)

Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans
por: Erle, Annette, et al.
Publicado: (2021)

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging
por: Tolkach, Yuri, et al.
Publicado: (2019)

Solid Tumor-Targeting Theranostic Polymer Nanoparticle in Nuclear Medicinal Fields
por: Makino, Akira, et al.
Publicado: (2014)

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
por: Montemagno, Christopher, et al.
Publicado: (2020)

Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA
por: Moazemi, Sobhan, et al.
Publicado: (2021)

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
por: Barca, Cristina, et al.
Publicado: (2021)

(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
por: Assadi, Majid, et al.
Publicado: (2019)

The Evolving Role of Nuclear Medicine and Molecular Imaging: Theranostics and Personalized Therapeutic Applications
por: Bozkurt, M. Fani, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cojq67mvphg2aofhaon79dl1os